1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Vital Signs The Analyst%s Perspective - August 2015 Issue 

Vital Signs The Analyst%s Perspective - August 2015 Issue 

  • September 2015
  • -
  • Frost & Sullivan
  • -
  • 6 pages

Vital Signs The Analyst's Perspective - August 2015 Issue

This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

Table Of Contents

Vital Signs The Analyst%s Perspective - August 2015 Issue 
LIFE SCIENCES
FDA Clears First 3D Printed Prescription Drug 2
Illumina, Inc and Investors Form Consumer Genomics Company Helix 3
Response Genetics Enters Into Asset Purchase Agreement with Cancer Genetics 4
Roche's Acquisition Spree Continues with its Purchase of GeneWEAVE
for $425 Million 5

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

  • $ 2995
  • Industry report
  • October 2016
  • by Currentpartnering

The Global Companion Diagnostics Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the ...

Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts

Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts

  • $ 2995
  • Industry report
  • September 2016
  • by Currentpartnering

The Global Molecular Diagnostics Partnering 2010-2016 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be ...

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 500
  • Industry report
  • November 2016
  • by Cancer Research Analytics

“Adcetris: 2011-2015 analysis; 2016-2021 expectations” is a comprehensive report on the first and only approved drug of Seattle Genetics called Adcetris, which is also the first drug approved by the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.